严重嗜酸性粒细胞性哮喘患者使用美泊利单抗后出现矛盾性不良反应并伴有美泊利单抗诱导的脱发病例。
Case of paradoxical adverse response to mepolizumab with mepolizumab-induced alopecia in severe eosinophilic asthma.
作者信息
Nixon Rodanthe, Despiney Raquel, Pfeffer Paul
机构信息
Barts Health NHS Trust, London, UK.
Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
出版信息
BMJ Case Rep. 2020 Feb 20;13(2):e233161. doi: 10.1136/bcr-2019-233161.
Abstract
Recent years have seen an increase in use of mepolizumab and other biological therapies for the treatment of severe eosinophilic asthma. A few cases of paradoxical responses to mepolizumab therapy have now been reported and are hypothesised as being a response to immune complex formation. We present a case of mepolizumab-induced alopecia in a patient with paradoxical adverse response to mepolizumab given for severe eosinophilic asthma. We postulate this could be secondary to autoimmune mechanisms and that it could help herald poor response to treatment, thereby facilitating early identification of patients having paradoxical responses.
摘要
近年来，美泊利单抗及其他生物疗法在重度嗜酸性粒细胞性哮喘治疗中的应用有所增加。现已报告了几例美泊利单抗治疗出现矛盾反应的病例，据推测这是对免疫复合物形成的一种反应。我们报告了1例因重度嗜酸性粒细胞性哮喘接受美泊利单抗治疗出现矛盾不良反应的患者发生美泊利单抗诱发脱发的病例。我们推测这可能继发于自身免疫机制，并且可能预示治疗反应不佳，从而有助于早期识别出现矛盾反应的患者。
相似文献
1
Case of paradoxical adverse response to mepolizumab with mepolizumab-induced alopecia in severe eosinophilic asthma.严重嗜酸性粒细胞性哮喘患者使用美泊利单抗后出现矛盾性不良反应并伴有美泊利单抗诱导的脱发病例。
BMJ Case Rep. 2020 Feb 20;13(2):e233161. doi: 10.1136/bcr-2019-233161.
2
Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety.美泊利珠单抗附加疗法在重度嗜酸性粒细胞性哮喘真实世界队列中的应答率、有效性及安全性
J Asthma. 2021 May;58(5):651-658. doi: 10.1080/02770903.2020.1723623. Epub 2020 Feb 12.
3
Mepolizumab (Nucala) for severe eosinophilic asthma.美泊利单抗（Nucala）用于治疗重度嗜酸性粒细胞性哮喘。
Med Lett Drugs Ther. 2016 Jan 18;58(1486):11-2.
4
Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.从奥马珠单抗转换为美泊利珠单抗：来自意大利南部的真实临床经验。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620929231. doi: 10.1177/1753466620929231.
5
Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.重度嗜酸性粒细胞性哮喘：从白细胞介素-5的致病作用到美泊利珠单抗的治疗作用
Drug Des Devel Ther. 2017 Oct 30;11:3137-3144. doi: 10.2147/DDDT.S150656. eCollection 2017.
6
Benralizumab (Fasenra) for severe eosinophilic asthma.用于重度嗜酸性粒细胞性哮喘的贝那利珠单抗（法泽拉）
Med Lett Drugs Ther. 2018 Feb 26;60(1541):33-35.
7
Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis.美泊利珠单抗治疗重度嗜酸性粒细胞性哮喘：希腊哮喘专科诊所 2 年随访结果：中期分析。
Int Arch Allergy Immunol. 2020;181(8):613-617. doi: 10.1159/000508559. Epub 2020 Jun 22.
8
Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.根据患者特征，重度嗜酸性粒细胞性哮喘换用美泊利珠单抗相比于奥马珠单抗的获益。
Respir Res. 2021 May 10;22(1):144. doi: 10.1186/s12931-021-01733-9.
9
Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma.按年龄和哮喘发病年龄划分的可接受美泊利珠单抗治疗的重度哮喘患者比例。
J Allergy Clin Immunol Pract. 2019 Nov-Dec;7(8):2689-2696.e2. doi: 10.1016/j.jaip.2019.05.053. Epub 2019 Jun 13.
10
Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma.美泊利珠单抗治疗重度嗜酸性粒细胞性哮喘真实世界队列患者的疗效和安全性。
J Asthma. 2021 Jan;58(1):79-84. doi: 10.1080/02770903.2019.1658208. Epub 2019 Sep 3.
引用本文的文献
1
Real-World Safety Profile of Biologic Drugs for Severe Uncontrolled Asthma: A Descriptive Analysis from the Spanish Pharmacovigilance Database.生物制剂治疗重度难治性哮喘的真实世界安全性概况：来自西班牙药物警戒数据库的描述性分析
J Clin Med. 2024 Jul 18;13(14):4192. doi: 10.3390/jcm13144192.
2
Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database.重度哮喘生物疗法的安全性：对世界卫生组织药物警戒数据库中报告的疑似不良反应的分析。
BioDrugs. 2024 May;38(3):425-448. doi: 10.1007/s40259-024-00653-6. Epub 2024 Mar 15.
3
A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database.一项在FDA不良事件报告系统（FAERS）数据库中进行的美泊利单抗真实世界药物警戒研究。
Front Pharmacol. 2023 Dec 21;14:1320458. doi: 10.3389/fphar.2023.1320458. eCollection 2023.
4
Risks and safety of biologics: A practical guide for allergists.生物制剂的风险与安全性：过敏症专科医生实用指南。
World Allergy Organ J. 2023 Jan 16;16(1):100737. doi: 10.1016/j.waojou.2022.100737. eCollection 2023 Jan.
5
Case of benralizumab-induced exacerbations of chronic spontaneous urticaria.倍利珠单抗诱发慢性自发性荨麻疹加重的病例。
Clin Case Rep. 2022 Jun 19;10(6):e05930. doi: 10.1002/ccr3.5930. eCollection 2022 Jun.
6
New Biologics for the Treatment of Atopic Dermatitis: Analysis of Efficacy, Safety, and Paradoxical Atopic Dermatitis Acceleration.新型生物制剂治疗特应性皮炎：疗效、安全性和特应性皮炎加速现象分析。
Biomed Res Int. 2021 May 30;2021:5528372. doi: 10.1155/2021/5528372. eCollection 2021.
本文引用的文献
1
Autoimmune Responses in Severe Asthma.重度哮喘中的自身免疫反应
Allergy Asthma Immunol Res. 2018 Sep;10(5):428-447. doi: 10.4168/aair.2018.10.5.428.
2
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.度普利尤单抗在中重度未控制哮喘中的疗效和安全性。
N Engl J Med. 2018 Jun 28;378(26):2486-2496. doi: 10.1056/NEJMoa1804092. Epub 2018 May 21.
3
Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma.瑞利珠单抗治疗嗜酸性粒细胞性哮喘患者的长期安全性和疗效。
J Allergy Clin Immunol Pract. 2017 Nov-Dec;5(6):1572-1581.e3. doi: 10.1016/j.jaip.2017.08.024.
4
Anti-IL5 therapies for asthma.用于哮喘的抗白细胞介素-5疗法。
Cochrane Database Syst Rev. 2017 Sep 21;9(9):CD010834. doi: 10.1002/14651858.CD010834.pub3.
5
Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.体重调整的静脉注射瑞利珠单抗治疗对固定剂量皮下美泊利珠单抗应答不足的重症哮喘。
Am J Respir Crit Care Med. 2018 Jan 1;197(1):38-46. doi: 10.1164/rccm.201707-1323OC.
6
Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy.低剂量美泊利单抗治疗后重度嗜酸性粒细胞性哮喘的气道自身免疫反应
Allergy Asthma Clin Immunol. 2017 Jan 6;13:2. doi: 10.1186/s13223-016-0174-5. eCollection 2017.
7
Current concepts of severe asthma.重度哮喘的当前概念
J Clin Invest. 2016 Jul 1;126(7):2394-403. doi: 10.1172/JCI84144.
8
Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicity.理解药物不良反应基因组学基础的进展：全面综述及对种族因素作用的关注
Pharmacogenomics. 2015;16(10):1161-78. doi: 10.2217/pgs.15.54. Epub 2015 May 15.
9
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma.国际 ERS/ATS 指南：严重哮喘的定义、评估和治疗。
Eur Respir J. 2014 Feb;43(2):343-73. doi: 10.1183/09031936.00202013. Epub 2013 Dec 12.
10
Treatment of patients with the hypereosinophilic syndrome with mepolizumab.使用美泊利珠单抗治疗高嗜酸性粒细胞综合征患者。
N Engl J Med. 2008 Mar 20;358(12):1215-28. doi: 10.1056/NEJMoa070812. Epub 2008 Mar 16.
Zotero 插件